Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
Gout
About this trial
This is an interventional diagnostic trial for Gout focused on measuring Uric Acid, xanthine oxidase, tophi, Drug Therapy
Eligibility Criteria
Inclusion Criteria: Hyperuricemia (serum uric acid ≥8.0 mg/dL). Must meet American College of Rheumatology criteria for gout. Must have adequate renal function (serum creatinine <1.5 mg/dL). Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. Exclusion Criteria: History of xanthinuria Alcohol consumption >14/week Has a history of significant concomitant illness. Has active liver disease. Has a body mass index greater than 50 kilogram per meter² (kg/m²) Any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Placebo Comparator
Experimental
Experimental
Experimental
Placebo QD
Febuxostat 40 mg QD
Febuxostat 80 mg QD
Febuxostat 120 mg QD